

We claim:

1. A method for treating fungal infections in a mammal, comprising administering a therapeutically effective amount of a composition comprising amphotericin B and a pharmaceutically acceptable carrier, wherein the amphotericin B is substantially pure.
2. The method of claim 1, wherein the amphotericin B is greater than about 96% pure.
- 10 3. The method of claim 1, wherein the amphotericin B is greater than about 98% pure.
4. The method of claim 1, wherein said pharmaceutically acceptable carrier is a lipid carrier.
- 15 5. The method of claim 1, wherein the administering step is intravenous.
6. A pharmaceutical composition, comprising substantially pure amphotericin B and a pharmaceutically acceptable carrier.
- 20 7. The composition of claim 6, wherein the amphotericin is greater than about 96% pure.
- 25 8. The composition of claim 6, wherein the amphotericin is greater than about 98% pure.
9. A pharmaceutical composition comprising an amphotericin B formulation, wherein the amphotericin B formulation comprises no greater than about 4% by weight of impurities.
- 30 10. A method of treating fungal infections in a mammal, comprising:

- providing an amphotericin B composition;
isolating impurities from said amphotericin B composition to form substantially pure amphotericin B;
forming a pharmaceutical composition with said substantially pure amphotericin B; and
administering a therapeutically effective amount of said pharmaceutical composition to said mammal.
11. The method of claim 10, wherein said isolation step comprises high pressure liquid chromatography fractionation.
12. The method of claim 10, wherein the substantially pure amphotericin B is greater than about 96% pure.
- 15 13. The method of claim 10, wherein the substantially pure amphotericin B is greater than about 98% pure.
14. The method of claim 10, wherein the forming a pharmaceutical composition step of comprises lipid carrier encapsulation of the highly purified amphotericin B.
- 20
15. The method of claim 10, wherein said administering step is intravenous.
16. A method of treating fungal infections in a mammal, comprising:
providing an amphotericin B product;
filtering said amphotericin B product to isolate impurities and form at least 96% pure amphotericin B;
forming a pharmaceutical composition with said at least 96% pure amphotericin B; and
administering a therapeutically effective amount of said pharmaceutical composition to said mammal.
- 30